CCUN Helps FDA Launch Clinical Trials of New MM Treatments
FDA approval of clinical trials based on minimal residual disease eradication represents a critical step forward for patients with multiple myeloma.
A report prepared by the international consortium i2TEAMM, of which the Cancer Center of the Clínica Universidad de Navarra (CCUN) is a part, has helped the US Food and Drug Administration (FDA) approve the launch of clinical trials of new treatments in patients with multiple myeloma. … + read more
CRIS Against Cancer Donates Over $3 Million to CCUN Cancer Research
The foundation supports the fight against melanoma, multiple myeloma, lung, ovarian and kidney cancer. + read more
Spain needs clinical research network to be a leader in Europe
Clinical researchers, the pharmaceutical industry and the Spanish Agency for Medicines and Health Products came together at a meeting organised by CCUN to maintain the country’s leadership and attractiveness in promoting Phase I cancer research. + more
Dagger Cells: Beyond CAR-T in Multiple Myeloma
According to a study conducted by the CNIO and the University Hospital on October 12, a new immunotherapy against multiple myeloma shows greater efficacy in the laboratory than the already used CAR-T. + read more
The European Union, with the support of CCUN, promotes lung cancer screening among women
The SOLACE project is launching an information campaign to ensure that women benefit from early detection of diseases that have tripled in the last two decades. + read more
Getting Closer to Preventing Symptomatic Multiple Myeloma
Today it is known that a patient with multiple myeloma does not have all the clinical manifestations of the disease, but rather has a precancerous phase in which one or another marker can be detected. + read more
CCUN, VHIO and Princess Margaret join forces in the fight against pancreatic cancer
AstraZeneca is funding a $2 million research project led by the Oncology Center of the University Hospital of Navarra that will seek to understand the changes induced by chemotherapy in the microenvironment of pancreatic tumors. + read more